首页> 美国卫生研究院文献>Molecular Cellular Proteomics : MCP >Large-Scale Interlaboratory Study to Develop Analytically Validate and Apply Highly Multiplexed Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma
【2h】

Large-Scale Interlaboratory Study to Develop Analytically Validate and Apply Highly Multiplexed Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma

机译:大规模的实验室间研究以开发分析验证和应用高度复用的定量肽测定法来测量血浆中与癌症相关的蛋白质

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is an increasing need in biology and clinical medicine to robustly and reliably measure tens to hundreds of peptides and proteins in clinical and biological samples with high sensitivity, specificity, reproducibility, and repeatability. Previously, we demonstrated that LC-MRM-MS with isotope dilution has suitable performance for quantitative measurements of small numbers of relatively abundant proteins in human plasma and that the resulting assays can be transferred across laboratories while maintaining high reproducibility and quantitative precision. Here, we significantly extend that earlier work, demonstrating that 11 laboratories using 14 LC-MS systems can develop, determine analytical figures of merit, and apply highly multiplexed MRM-MS assays targeting 125 peptides derived from 27 cancer-relevant proteins and seven control proteins to precisely and reproducibly measure the analytes in human plasma. To ensure consistent generation of high quality data, we incorporated a system suitability protocol (SSP) into our experimental design. The SSP enabled real-time monitoring of LC-MRM-MS performance during assay development and implementation, facilitating early detection and correction of chromatographic and instrumental problems. Low to subnanogram/ml sensitivity for proteins in plasma was achieved by one-step immunoaffinity depletion of 14 abundant plasma proteins prior to analysis. Median intra- and interlaboratory reproducibility was <20%, sufficient for most biological studies and candidate protein biomarker verification. Digestion recovery of peptides was assessed and quantitative accuracy improved using heavy-isotope-labeled versions of the proteins as internal standards. Using the highly multiplexed assay, participating laboratories were able to precisely and reproducibly determine the levels of a series of analytes in blinded samples used to simulate an interlaboratory clinical study of patient samples. Our study further establishes that LC-MRM-MS using stable isotope dilution, with appropriate attention to analytical validation and appropriate quality control measures, enables sensitive, specific, reproducible, and quantitative measurements of proteins and peptides in complex biological matrices such as plasma.
机译:在生物学和临床医学中,越来越需要以高灵敏度,特异性,可重复性和可重复性来可靠,可靠地测量临床和生物学样品中的数十至数百种肽和蛋白质。以前,我们证明了具有同位素稀释作用的LC-MRM-MS在定量测定人血浆中少量的相对丰富的蛋白质方面具有合适的性能,并且所产生的测定法可以在保持高重现性和定量精度的同时跨实验室转移。在这里,我们大大扩展了早期的工作,证明了使用14个LC-MS系统的11个实验室可以开发,确定性能指标并应用高度多重的MRM-MS分析,靶向来自27种与癌症相关的蛋白和7种对照蛋白的125种肽精确和可重复地测量人体血浆中的分析物。为确保始终如一的高质量数据生成,我们将系统适用性协议(SSP)纳入了我们的实验设计。 SSP能够在化验开发和实施过程中实时监控LC-MRM-MS的性能,从而有助于及早发现并纠正色谱和仪器问题。通过在分析之前对14种丰富的血浆蛋白进行一步免疫亲和去除,可以实现血浆蛋白的低至亚纳克/毫升敏感性。实验室内和实验室间的可重复性中值<20%,足以进行大多数生物学研究和候选蛋白质生物标志物验证。使用重同位素标记的蛋白质作为内标,评估了肽的消化回收率并提高了定量准确性。使用高度复用的测定法,参与的实验室能够精确,可重复地确定用于模拟患者样品实验室间临床研究的盲样品中一系列分析物的水平。我们的研究进一步证明,使用稳定的同位素稀释液进行LC-MRM-MS,同时注意分析验证和适当的质量控制措施,可以对复杂的生物基质(例如血浆)中的蛋白质和多肽进行灵敏,特异,可再现和定量的测量。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号